Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 16/20 | 0.60 |
| ▸ | FNTB | P49356 | 14/20 | 0.60 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.60 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3510870 | 1.00 | FNTA (0.60) | FNTAFNTBPGGT1BGGPS1 | |
| SCHEMBL639030 | 0.90 | FNTA (0.51) | FNTAFNTBPGGT1BGGPS1 | |
| SCHEMBL8054373 | 0.80 | FNTA (0.59) | FNTAFNTBPGGT1BGGPS1 | |
| SCHEMBL23802598 | 0.78 | FNTA (0.57) | FNTAFNTBPGGT1BGGPS1 | |
| SCHEMBL155329 | 0.78 | FNTA (0.57) | FNTAFNTBPGGT1BGGPS1 | |
| SCHEMBL10933152 | 0.78 | KMT2A (0.52) | FNTAFNTB | |
| Ammonia Solution, Strong SCHEMBL2828987 | 0.77 | FNTA (0.56) | FNTAFNTBPGGT1BGGPS1 | |
| Methane SCHEMBL20839372 | 0.77 | FNTA (0.56) | FNTAFNTBPGGT1BGGPS1 | |
| SCHEMBL23802599 | 0.76 | FNTA (1.00) | FNTAFNTBPGGT1B | |
| SCHEMBL23610949 | 0.76 | FNTA (1.00) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170081690-A1 | MOENOMYCIN BIOSYNTHESIS-RELATED COMPOSITIONS AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-23 | — | — | US | disclosed |
| US-9115358-B2 | Moenomycin biosynthesis-related compositions and methods of use thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-08-25 | — | — | US | disclosed |
| US-20100279980-A1 | MOENOMYCIN BIOSYNTHESIS-RELATED COMPOSITIONS AND METHODS OF USE THEREOF | PRESIDENT AND FELLOW OF HARWARD COLLEGE | 2010-11-04 | — | — | US | disclosed |
| WO-2008021367-A2 | MOENOMYCIN BIOSYNTHESIS-RELATED COMPOSITIONS AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279980-A1 | MOENOMYCIN BIOSYNTHESIS-RELATED COMPOSITIONS AND METHODS OF USE THEREOF | MGAM, GALE, GMDS | FNTA 114/4885FNTB 226/4885PGGT1B 215/4885 |
| US-20170081690-A1 | MOENOMYCIN BIOSYNTHESIS-RELATED COMPOSITIONS AND METHODS OF USE THEREOF | MGAM, GALE, GMDS | FNTA 114/4885FNTB 226/4885PGGT1B 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.